COVID-19 in ocrelizumab-treated people with multiple sclerosis

Richard Hughes, Louise Whitley,Kocho Fitovski,Hans-Martin Schneble,Erwan Muros,Annette Sauter,Licinio Craveiro,Paul Dillon,Ulrike Bonati,Nikki Jessop,Rosetta Pedotti,Harold Koendgen

Multiple Sclerosis and Related Disorders（2021）

引用 54|浏览13

暂无评分

摘要

•COVID-19 severity was in line with that of the general population and MS datasets•Most patients did not require hospitalization•There was no association between duration of exposure to ocrelizumab and COVID-19•Patients with known COVID-19 risk factors had more severe COVID-19•Case fatality rates were comparable with other MS cohorts

查看译文

关键词

COVID-19,multiple sclerosis,ocrelizumab,disease-modifying therapy,anti-CD20

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要